Craig A. Mullen, M.D., Ph.D.

Craig A. Mullen, M.D., Ph.D.

Contact Information

University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 777
Rochester, NY 14642

Office: (585) 275-2981
Fax: (585) 273-1039
Lab: (585) 275-1571

Professional Bio

Dr. Mullen serves as the Chief of the Pediatric Hematology / Oncology Division. He is also the Director the Fellowship Program, and leads the Experimental Hematology Program at the University of Rochester. He has joint appointments as Professor in both the Department of Microbiology and Immunology and Professor in the Department of Oncology.

Research Bio

Dr. Mullen's research interests are: Cancer Immunobiology and Transplant Immunology.

The goal of Dr. Mullen's research is to use murine models of allogeneic hematopoietic stem cell (HSC) transplantation to identify immunological mechanisms that can be used to design therapies that will reduce the likelihood of leukemia relapse after allogeneic HCS transplant in children with leukemia. In allogeneic HSC transplant the graft versus leukemia (GVL) effect is closely associated with GVHD and clinical attempts to separate the two have not been successful. In the absence of specific immune manipulation the dominant allogeneic immune response that develops after transplant is directed at immunodominant, widely distributed host antigens, and the post-transplant environment does not favor development of immune responses with relative selectively for antigens on minimal residual leukemia.

His laboratory has recently demonstrated that allogeneic HSC transplant recipients treated after transplant with cellular tumor vaccines exhibit prolonged survival but do not experience exacerbations of GVHD. The mechanism of this vaccine effect is under investigation. The central hypothesis in this work is that post-transplant tumor vaccines can enhance systemic immune responses that can control minimal residual leukemia without exacerbation of clinically significant graft versus host disease.

Active projects in the lab include the following:

1)Testing the hypothesis that after allogeneic hematopoietic stem cell transplantation moderate affinity T cells specific for subdominant minor histocompatibility antigens can be activated by vaccines to exert antileukemia activity without GVHD.

2) Testing the hypothesis that allogeneic delayed lymphocyte infusion for acute lymphoblastic malignancies can be made more effective by simultaneous vaccination against leukemia associated antigens.

3) To identify the leukemia associated antigenic targets of T cells induced by post-transplant tumor vaccines and to determine if these empirically identified genes correlate with classes of genes predicted to be antigenic based on gene expression analysis.

Awards & Honors (Local)

Award for Second International Symposium on Minor Histocompatibility Antigens | International Congress of Histocompatibility and Immunogenetics 2002
Dean's Excellence Award | Graduate School of Biomedical Sciences | University of Texas-Houston Health Science Center 1999
American Association of Cancer Research | Upjohn Travel Award 1992
Alpha Omega Alpha 1986
Dr. Harold Lamport Biomedical Research Award (for the best PhD dissertation in biomedical research) | University of Chicago 1986
Phi Beta Kappa 1978

Recent Journal Articles

Showing the 5 most recent journal articles. 78 available »

Oyeku SO, Driscoll MC, Cohen HW, Trachtman R, Pashankar R, Mullen C, Giardina PJ, Velazco N, Racine AD, Green NS. "Parental and other factors associated with hydroxyurea use for pediatric sickle cell disease." Pediatric Blood and Cancer. 2013; 60: 653-658.
Green NS, Ender KL, Pashankar F, Driscoll C, Giardina PJ, Mullen CA, Clark LN, Manwani D, Crotty J, Kisselev S, Neville KA, Hoppe C, Barral S. "Candidate sequence variants and fetal hemoglobin in children with sickle cell dsiease treated with hydroxyurea." PLoS ONE. 2013; 8(2): e55709.
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR. "Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious disease society of america." Clin Infect Dis. 2011; 4: 427-31.
Milner LA, Becker M, Bernstein S, Bruckner L, Friedberg J, Holand G, Ifthikharuddin J, Liesveld J, Mathes E, Menchel H, Mullen CA, Sasson T, Phillips GL. "Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease." American Journal of Hematology. 2011; 86(8): 712-714.
Shand JC, Jansson J, Hsu Y-C, Campbell A and Mullen CA. "Differential gene expression in acute lymphoblastic leukemia cells surviving allogeneic transplant." Cancer Immunology Immunotherapy. 2010; .

Current Appointments

Professor - Department of Pediatrics, Hematology and Oncology (SMD) - Primary
Professor - Department of Microbiology and Immunology (SMD)
Professor - Cancer Center


Pediatrics - American Board of Pediatrics
Pediatric Hematology-Oncology - American Board of Pediatrics


MD | Medicine | University of Chicago - Pritzker School of Medicine1986
PhD | Pathology | University of Chicago1984
BS | Molecular Biology | University of Wisconsin1979

Post-Doctoral Training & Residency

Research in Immunohematology at National Institute of Health07/01/1992 - 6/30/94
Fellowship in Pediatric Hematology/Oncology at National Institute of Health07/01/1989 - 06/30/1992
Residency in Pediatrics at Children's Medical Center of Dallas07/01/1987 - 06/30/1989
Internship in Pediatrics at Children's Medical Center of Dallas07/01/1986 - 06/30/1987